Sermorelin Mechanism of Action — Research Reference

Sermorelin is the GHRH(1-29) fragment — the shortest sequence of native human GHRH that retains full receptor activity. It is the historical reference compound in growth hormone-axis research.

Receptor Target

Sermorelin binds the GHRH receptor (GHRH-R) on anterior pituitary somatotropes with affinity comparable to endogenous GHRH (1-44). It does not act on the ghrelin receptor (GHS-R1a).

Signal Transduction

GHRH-R is a class-B GPCR. Sermorelin binding activates:

1. Gαs → adenylyl cyclase → cAMP → PKA — primary pathway; drives Ca²⁺-dependent GH-vesicle exocytosis.
2. CREB-mediated GH gene transcription — maintains somatotrope GH content during sustained signalling.
3. MAPK/ERK — contributes to somatotrope trophic effects.

Pharmacokinetics

Sermorelin's plasma half-life is approximately 10–20 minutes — close to native GHRH and substantially shorter than DPP-IV-resistant analogues (CJC-1295, tesamorelin). Subcutaneous administration produces a discrete GH pulse that closes within 60–90 minutes.

Pulse-Preserving Profile

Because the signal terminates quickly, sermorelin amplifies endogenous GH pulses rather than overriding them. This preserves the circadian GH-pulse architecture and explains why pre-sleep dosing is the dominant timing in the published research — it captures the natural nocturnal pulse without flattening day-time rhythm.

Synergy with GHRPs

The GHRH receptor and ghrelin receptor converge on the same somatotrope. Sermorelin + a GHRP (ipamorelin, GHRP-2) produces synergistic GH release because the two pathways combine Gαs/cAMP elevation with Gαq/Ca²⁺ mobilization on a single cell.

Research Use Only. All content is for laboratory research and educational reference. Compounds discussed are not intended for human or veterinary consumption.

References

1. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307–308.
2. Mayo KE, Miller T, DeAlmeida V, et al. The growth-hormone-releasing hormone receptor. Recent Prog Horm Res. 1995;50:35–73.
3. Vance ML, Kaiser DL, Evans WS, et al. Pulsatile growth hormone secretion in normal man during continuous 24-hour infusion of human growth hormone releasing factor. J Clin Invest. 1985;75(5):1584–1590.